859 Shares in Celgene Co. (CELG) Acquired by Guidant Wealth Advisors
Guidant Wealth Advisors acquired a new position in shares of Celgene Co. (NASDAQ:CELG) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 859 shares of the biopharmaceutical company’s stock, valued at approximately $119,000.
Other large investors have also added to or reduced their stakes in the company. Thompson Davis & CO. Inc. raised its holdings in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI grew its holdings in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. Motco grew its holdings in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Celgene during the 2nd quarter valued at $129,000. Finally, Balentine LLC grew its holdings in Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 481 shares during the last quarter. 79.84% of the stock is owned by institutional investors and hedge funds.
Celgene Co. (NASDAQ CELG) opened at $106.33 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market capitalization of $84,935.75, a price-to-earnings ratio of 25.26, a P/E/G ratio of 0.84 and a beta of 1.78. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. analysts predict that Celgene Co. will post 6.68 earnings per share for the current fiscal year.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.95% of the company’s stock.
Several equities research analysts have recently issued reports on the company. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective on the stock. in a report on Monday, December 18th. Credit Suisse Group set a $123.00 price objective on Celgene and gave the stock a “buy” rating in a report on Friday. Oppenheimer set a $166.00 price objective on Celgene and gave the stock a “buy” rating in a report on Friday. Citigroup restated a “hold” rating on shares of Celgene in a report on Friday. Finally, Cantor Fitzgerald restated a “buy” rating and set a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus price target of $135.43.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.